Impact of Peroxisome Proliferator-Activated Receptor Agonists on Myosteatosis in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease

Nathan Boliaki, Guillaume Henin, Georgia Bale, Nicolas Lanthier

PDF(5425 KB)
For Authors|For Editors|For Reviewers
PDF(5425 KB)
Discovery Medicine ›› 2024, Vol. 36 ›› Issue (185) : 1139-1153. DOI: 10.24976/Discov.Med.202436185.104
Review

Impact of Peroxisome Proliferator-Activated Receptor Agonists on Myosteatosis in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease

    {{javascript:window.custom_author_en_index=0;}}
  • {{article.zuoZhe_EN}}
Author information +
History +

Highlight

{{article.keyPoints_en}}

Abstract

{{article.zhaiyao_en}}

Key words

Cite this article

EndNote

Ris (Procite)

Bibtex

Download Citations
{{article.zuoZheEn_L}}. {{article.title_en}}. {{journal.qiKanMingCheng_EN}}. 2024, 36(185): 1139-1153 https://doi.org/10.24976/Discov.Med.202436185.104

References

Publishing order | Descend order by publishing year | Descend order by cited within

References

{{article.reference}}

Funding

RIGHTS & PERMISSIONS

{{article.copyrightStatement_en}}
{{article.copyrightLicense_en}}
PDF(5425 KB)

Accesses

Citation

Detail
Sections
Recommended
Follow Us on
Copyright © 2025.
By using this website, you agree to our Terms & Conditions and Privacy Policy.  
  • Disclaimer
    The statements, opinions and data contained in Discovery Medicine are solely those of the individual authors and contributors and not of the journal and the editor(s). Discovery Medicine stays neutral with regard to jurisdictional claims in published maps and institutional affiliations.

    • /

    〈 〉